STATEMENT: P4AD Applauds FDA’s Approval Of First Interchangeable Biosimilar Insulin, Calls For Affordable Insulin For All
The FDA’s approval of Semglee as an interchangeable biosimilar to Lantus is an important step forward on the road to real competition.
Patients For Affordable Drugs’ Analysis Highlights Need For Medicare Negotiation For All Drugs
Take a look at this year's price hikes to see why Congress must act now.
TODAY: Patient, P4AD Founder David Mitchell Tells Senate Judiciary Subcommittee That Anticompetitive Pharma Industry Practices Stifle Innovation, Drive Up Prices
Mitchell Urges Congress To Pass Bipartisan Solutions To Address Anticompetitive Behavior And To Allow Medicare To Negotiate Lower Drug Prices
Pharmaceutical Industry’s Financial Power And Influence Remain Strong And Far-Reaching As Drug Pricing Legislation Moves Forward
STATEMENT: Patients For Affordable Drugs Supports Alzheimer’s Association’s Denunciation Of Aduhelm’s Price Set By Biogen
"We stand with the Alzheimer’s Association in its denunciation of the price set by Biogen for the drug Aduhelm."